Recently, Stanford University in the United States released the "Top 2% of Global Scientists List for 2025". This list selects the scientists with the most "lifelong scientific influence" and "2025 scientific influence" worldwide through modeling and analysis of parameters such as the number of published papers and citation counts. Dr. Han Guohong from the Digestive Disease Hospital of Xi'an International Medical Center Hospital has been successfully selected for the "2025 Scientific Influence" list due to his outstanding contributions in the fields of gastroenterology and liver disease. So far, President Han Kuo hung has been selected for this authoritative list for three consecutive years.

The "Top 2% Global Scientists List" is known for its transparency and authority. It uses six comprehensive indicators, including total citation count, personal h-factor, co authorship corrected Hm factor, and citation count of individual, first, or last author articles. It is divided into 22 fields and 176 sub fields, and systematically and objectively reflects the academic contributions and research influence of scientists worldwide from two dimensions: "career influence" and "annual influence".

As an internationally recognized academic ranking, this list has included many Nobel laureates, such as Tu Youyou, Yang Zhenning, Qian Yongjian, etc., reflecting the global influence and important contributions of the selected scholars in their professional fields. In the "Scientific Influence" list for the year 2025, a total of 87 scholars from China were selected in the field of gastroenterology/hepatology, with Dean Han Kuo hung among them, indicating that his research achievements have been widely recognized by international peers.
This selection not only highly recognizes the personal research strength of Dr. Han Kuo hung, but also demonstrates the international level of the hospital in clinical and research of digestive system diseases. Xi'an International Medical Center Hospital will continue to increase investment in scientific research and innovation, optimize innovation platforms and talent mechanisms, promote the development of more high-level and original research, and contribute to enhancing China's core competitiveness in medical science and technology.